JP2013501733A - １，３−プロパンジスルホン酸を送達するための方法、化合物、および組成物 - Google Patents

１，３−プロパンジスルホン酸を送達するための方法、化合物、および組成物 Download PDF

Info

Publication number
JP2013501733A
JP2013501733A JP2012524066A JP2012524066A JP2013501733A JP 2013501733 A JP2013501733 A JP 2013501733A JP 2012524066 A JP2012524066 A JP 2012524066A JP 2012524066 A JP2012524066 A JP 2012524066A JP 2013501733 A JP2013501733 A JP 2013501733A
Authority
JP
Japan
Prior art keywords
compound
alkyl
group
heteroaryl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2012524066A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013501733A5 (enExample
Inventor
コング，シェンチー
レーベンス，ナイジェル
ボウジド，アブデルラヒーム
シブラ，ステファン
フレネット，リチャード
レナウド，ジョアン
Original Assignee
ビーエイチアイ リミテッド パートナーシップ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビーエイチアイ リミテッド パートナーシップ filed Critical ビーエイチアイ リミテッド パートナーシップ
Publication of JP2013501733A publication Critical patent/JP2013501733A/ja
Publication of JP2013501733A5 publication Critical patent/JP2013501733A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/05—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing at least two sulfo groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58—One oxygen atom, e.g. butenolide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/20—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hydrogen atoms and substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D309/22—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/10—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms two oxygen atoms and one sulfur atom, e.g. cyclic sulfates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4025—Esters of poly(thio)phosphonic acids
    • C07F9/4043—Esters of poly(thio)phosphonic acids containing sulfur substituents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
JP2012524066A 2009-08-10 2010-08-06 １，３−プロパンジスルホン酸を送達するための方法、化合物、および組成物 Ceased JP2013501733A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23259709P 2009-08-10 2009-08-10
US61/232,597 2009-08-10
PCT/CA2010/001229 WO2011017800A1 (en) 2009-08-10 2010-08-06 Methods, compounds, and compositions for delivering 1,3-propan ed isulfonic acid

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015179480A Division JP2016034960A (ja) 2009-08-10 2015-09-11 １，３−プロパンジスルホン酸を送達するための方法、化合物、および組成物

Publications (2)

Publication Number Publication Date
JP2013501733A true JP2013501733A (ja) 2013-01-17
JP2013501733A5 JP2013501733A5 (enExample) 2013-08-29

Family

ID=43585812

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012524066A Ceased JP2013501733A (ja) 2009-08-10 2010-08-06 １，３−プロパンジスルホン酸を送達するための方法、化合物、および組成物
JP2015179480A Pending JP2016034960A (ja) 2009-08-10 2015-09-11 １，３−プロパンジスルホン酸を送達するための方法、化合物、および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015179480A Pending JP2016034960A (ja) 2009-08-10 2015-09-11 １，３−プロパンジスルホン酸を送達するための方法、化合物、および組成物

Country Status (15)

Country Link
US (2) US9051248B2 (enExample)
EP (1) EP2464626A4 (enExample)
JP (2) JP2013501733A (enExample)
KR (1) KR20120087878A (enExample)
CN (1) CN102471248B (enExample)
AU (1) AU2010282170B2 (enExample)
BR (1) BR112012002780A2 (enExample)
CA (1) CA2768877A1 (enExample)
EA (1) EA201290007A1 (enExample)
IL (1) IL217572A (enExample)
MX (1) MX2012001671A (enExample)
NZ (1) NZ598085A (enExample)
SG (2) SG10201600910YA (enExample)
WO (1) WO2011017800A1 (enExample)
ZA (1) ZA201201352B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013521270A (ja) * 2010-03-05 2013-06-10 カンドュラ，マヘシュ 化合物、組成物、製剤、およびそれらの使用
JP2016034960A (ja) * 2009-08-10 2016-03-17 ビーエイチアイ リミテッド パートナーシップ １，３−プロパンジスルホン酸を送達するための方法、化合物、および組成物
JP2021024830A (ja) * 2019-08-07 2021-02-22 東ソー・ファインケム株式会社 カルボン酸無水物またはスルホン酸無水物の製造方法

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
US9738631B2 (en) 2012-05-07 2017-08-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
JP2015522531A (ja) 2012-05-07 2015-08-06 セリックスビオ プライヴェート リミテッド 神経筋疾患及び神経変性疾患の治療のための組成物及び方法
US9309233B2 (en) 2012-05-08 2016-04-12 Cellix Bio Private Limited Compositions and methods for the treatment of blood clotting disorders
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
SG11201407318UA (en) 2012-05-10 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of metabolic syndrome
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9498461B2 (en) 2012-05-23 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
AU2013264820A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of mucositis
AU2013264896A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
CA2873029A1 (en) 2012-09-08 2014-03-13 Cellixbio Private Limited Compositions and methods for the treatment of inflammation and lipid disorders
CN103012463B (zh) * 2013-01-17 2016-02-10 南京理工大学 (s)-3-甲基-2-(叔丁基二甲基硅氧基)-1-溴丁烷的合成方法
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
SG11201509782TA (en) 2013-06-04 2015-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
CN103755679A (zh) * 2014-02-14 2014-04-30 宁德新能源科技有限公司 一种亚烷基二磺酸酐的制备方法
ES2721003T3 (es) 2014-04-30 2019-07-26 Icahn School Med Mount Sinai Utilización de ácido 1, 3 - propano disulfónico o sales farmacéuticamente aceptables del mismo para el tratamiento de la sarcoidosis
EP3240779B1 (en) 2014-09-26 2020-10-28 Cellixbio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
ES2799309T3 (es) 2014-09-29 2020-12-16 Cellix Bio Private Ltd Compuestos y composiciones para el tratamiento de esclerosis múltiple
CA2965449C (en) 2014-10-27 2020-11-10 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
CN107207411A (zh) 2014-12-01 2017-09-26 塞尔利克斯生物私人有限公司 用于治疗多发性硬化的组合物和方法
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
ES2905771T3 (es) 2015-01-06 2022-04-12 Cellix Bio Private Ltd Composiciones y procedimientos para el tratamiento de la inflamación y del dolor
CN109988085B (zh) * 2017-12-29 2021-11-09 张家港市国泰华荣化工新材料有限公司 金属离子含量低的1,3-丙二烷基磺酸的制备方法
EP3817810B1 (en) 2018-07-06 2025-09-17 Pfizer Inc. Manufacturing process and intermediates for a pyrrolo[2,3- d]pyrimidine compound and use thereof
JP7611824B2 (ja) 2018-11-22 2025-01-10 ナント ユニベルシテ 増殖性疾患の処置で使用するためのジスルホナートスチルベン
CN110818673B (zh) * 2019-11-22 2022-08-16 湖南阿斯达新材料有限公司 一种环状二磺酸亚甲酯的合成方法
CN112574167B (zh) * 2020-12-07 2021-11-09 烟台海川化学制品有限公司 一种甲烷二磺酸亚甲酯的制备方法
KR20240001118A (ko) * 2021-05-31 2024-01-03 미쯔비시 가스 케미칼 컴파니, 인코포레이티드 신규 아미노 화합물 및 그의 제조방법, 그리고, 이것을 이용한 에폭시 수지용 경화제, 에폭시 수지 조성물 및 에폭시 수지 경화물
CN115124502B (zh) * 2022-08-03 2024-09-13 张家港市国泰华荣化工新材料有限公司 一种丙烯二磺酸酐的制备方法

Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4895450A (enExample) * 1972-02-25 1973-12-07
DD119040A1 (enExample) * 1975-03-11 1976-04-05
JPS5251372A (en) * 1975-10-24 1977-04-25 Agfa Gevaert Ag New 11sulphonyll44aminoo pyridinium salt and preparation method thereof
JPS60209589A (ja) * 1984-04-02 1985-10-22 アメリカン・サイアナミド・カンパニ− セフアロスポリン誘導体のエステル
JPH0683056A (ja) * 1991-12-12 1994-03-25 American Teleph & Telegr Co <Att> デバイスの製造方法
JPH08506908A (ja) * 1993-02-01 1996-07-23 ヘキスト、アクチェンゲゼルシャフト スルホン酸エステル、それを使用して製造した放射線感応性混合物およびその使用
JPH11501635A (ja) * 1995-03-15 1999-02-09 クイーンズ ユニバーシティ アット キングストン アミロイド症の治療法
DE19823722A1 (de) * 1998-05-27 1999-12-02 Merckle Gmbh Chinolinylmethoxyaryl-Verbindungen als duale Inhibitoren der Cyclooxygenase und 5-Lipoxygenase
JP2003532656A (ja) * 1999-12-23 2003-11-05 ニューロケム インコーポレーティッド 脳のアミロイド性脈管障害を調節するための化合物及び方法
WO2004046153A1 (en) * 2002-11-21 2004-06-03 Ranbaxy Laboratories Limited Prodrug esters of ceftriaxone
JP2006162735A (ja) * 2004-12-03 2006-06-22 Fuji Photo Film Co Ltd 感光性組成物及び該感光性組成物を用いたパターン形成方法
JP2007516940A (ja) * 2003-06-23 2007-06-28 ニューロケム （インターナショナル） リミテッド 改善された薬剤候補およびその調製法
WO2008001212A2 (en) * 2006-06-28 2008-01-03 Pfizer Products Inc. Penem prodrugs
JP2009506051A (ja) * 2005-08-25 2009-02-12 シェーリング コーポレイション α２Ｃアドレナリン受容体アゴニスト
US20090069419A1 (en) * 2007-09-07 2009-03-12 Bernd Jandeleit Masked carboxylate neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
US20090082464A1 (en) * 2007-09-07 2009-03-26 Bernd Jandeleit Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
JP2009515862A (ja) * 2005-11-11 2009-04-16 サイクラセル リミテッド 増殖症の治療のためのロスコビチンとｈｄａｃ阻害剤との組合せ
US20090099253A1 (en) * 2007-10-15 2009-04-16 Xenoport, Inc. Internally Masked Neopentyl Sulfonyl Ester Cyclization Release Prodrugs of Acamprosate, Compositions Thereof, and Methods of Use
JP2009109595A (ja) * 2007-10-26 2009-05-21 Fujifilm Corp 電子線、ｘ線又はｅｕｖ用ポジ型レジスト組成物及びそれを用いたパターン形成方法
JP2010513219A (ja) * 2006-12-22 2010-04-30 ベラス ヘルス （インターナショナル） リミテッド 腎臓の疾患、糖尿病性腎症及び脂質代謝異常の治療

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB661537A (en) * 1948-11-24 1951-11-21 Rhone Poulenc Sa Improvements in and relating to the preparation of sulphonyl derivatives of piperazine
CA2107644A1 (en) * 1992-10-28 1994-04-29 David R. Magnin .alpha.-phosphonosulfonae squalene synthetase inhibitors and methd
EP0691844A1 (en) 1993-03-29 1996-01-17 Queen's University At Kingston Method for treating amyloidosis
US6562836B1 (en) 1999-05-24 2003-05-13 Queen's University Of Kingston Methods and compounds for inhibiting amyloid deposits
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
AU2004249529A1 (en) 2003-06-23 2004-12-29 Bellus Health (International) Limited Methods and compositions for treating amyloid-related diseases
US7253306B2 (en) * 2003-06-23 2007-08-07 Neurochem (International) Limited Pharmaceutical drug candidates and methods for preparation thereof
TW200716088A (en) 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
ATE481094T1 (de) 2005-12-22 2010-10-15 Kiacta Sarl Behandlung von diabetischer nephropathie
CA2673022A1 (en) 2006-12-22 2008-07-03 Bellus Health (International) Limited Methods, compounds, and compositions for treating metabolic disorders and diabetes
CN102471248B (zh) * 2009-08-10 2015-01-07 Bhi有限合伙公司 用于递送1,3-丙二磺酸的方法、化合物和组合物

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4895450A (enExample) * 1972-02-25 1973-12-07
DD119040A1 (enExample) * 1975-03-11 1976-04-05
JPS5251372A (en) * 1975-10-24 1977-04-25 Agfa Gevaert Ag New 11sulphonyll44aminoo pyridinium salt and preparation method thereof
JPS60209589A (ja) * 1984-04-02 1985-10-22 アメリカン・サイアナミド・カンパニ− セフアロスポリン誘導体のエステル
JPH0683056A (ja) * 1991-12-12 1994-03-25 American Teleph & Telegr Co <Att> デバイスの製造方法
JPH08506908A (ja) * 1993-02-01 1996-07-23 ヘキスト、アクチェンゲゼルシャフト スルホン酸エステル、それを使用して製造した放射線感応性混合物およびその使用
JPH11501635A (ja) * 1995-03-15 1999-02-09 クイーンズ ユニバーシティ アット キングストン アミロイド症の治療法
DE19823722A1 (de) * 1998-05-27 1999-12-02 Merckle Gmbh Chinolinylmethoxyaryl-Verbindungen als duale Inhibitoren der Cyclooxygenase und 5-Lipoxygenase
JP2003532656A (ja) * 1999-12-23 2003-11-05 ニューロケム インコーポレーティッド 脳のアミロイド性脈管障害を調節するための化合物及び方法
WO2004046153A1 (en) * 2002-11-21 2004-06-03 Ranbaxy Laboratories Limited Prodrug esters of ceftriaxone
JP2007516940A (ja) * 2003-06-23 2007-06-28 ニューロケム （インターナショナル） リミテッド 改善された薬剤候補およびその調製法
JP2006162735A (ja) * 2004-12-03 2006-06-22 Fuji Photo Film Co Ltd 感光性組成物及び該感光性組成物を用いたパターン形成方法
JP2009506051A (ja) * 2005-08-25 2009-02-12 シェーリング コーポレイション α２Ｃアドレナリン受容体アゴニスト
JP2009515862A (ja) * 2005-11-11 2009-04-16 サイクラセル リミテッド 増殖症の治療のためのロスコビチンとｈｄａｃ阻害剤との組合せ
WO2008001212A2 (en) * 2006-06-28 2008-01-03 Pfizer Products Inc. Penem prodrugs
JP2010513219A (ja) * 2006-12-22 2010-04-30 ベラス ヘルス （インターナショナル） リミテッド 腎臓の疾患、糖尿病性腎症及び脂質代謝異常の治療
US20090069419A1 (en) * 2007-09-07 2009-03-12 Bernd Jandeleit Masked carboxylate neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
US20090082464A1 (en) * 2007-09-07 2009-03-26 Bernd Jandeleit Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
US20090099253A1 (en) * 2007-10-15 2009-04-16 Xenoport, Inc. Internally Masked Neopentyl Sulfonyl Ester Cyclization Release Prodrugs of Acamprosate, Compositions Thereof, and Methods of Use
JP2009109595A (ja) * 2007-10-26 2009-05-21 Fujifilm Corp 電子線、ｘ線又はｅｕｖ用ポジ型レジスト組成物及びそれを用いたパターン形成方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN6014035366; Ｇｅｉｓｅｌｅｒ　Ｇ．　ｅｔ　ａｌ: Ｃｈｅｍｉｓｃｈｅ　Ｂｅｒｉｃｈｔｅ ９１．　Ｊａｈｒｇ．　Ｎｒ．９, 1958, ｐｐ．１８８１-１８９１ *
JPN6014035367; Ｂｕｌｌ．　Ｃｈｅｍ．　Ｓｏｃ．　Ｊｐｎ Ｖｏｌ．５６　Ｎｏ．４, 1983, ｐｐ．１２５７-１２５８ *
JPN7014002507; Ｅｓａｙａｎ　ｅｔ　ａｌ．: Ｉｚｕ．　Ａｋａｄ．　Ｎａｕｋ　Ａｒｍ．　ＳＳＲ，　Ｋｈｉｍ．　Ｎａｕｋｉ　ｖｏｌ．　１８　ｎｏ．３　ｐｐ．３０９-３１２ , 1965 *
JPN7014002508; Ｏｇａｎｅｓｙａｎ　Ｅ．　Ｅ．　ｅｔ　ａｌ: Ａｒｍ．　Ｋｈｉｍ．　Ｚｈ．　１９７５，　ｖｏｌ．　２８　ｎｏ．８　ｐｐ．６６９-７１ , 1976 *
JPN7014002509; Ｌｉｃｈｔｅｎｂｅｒｇｅｒ　Ｊ．　ｅｔ　ａｌ: Ｂｕｌｌｅｔｉｎ　ｄｅ　ｌａ　Ｓｏｃｉｅｔｅ　Ｃｈｉｍｉｑｕｅ　ｄｅ　Ｆｒａｎｃｅ , 1961, ｐｐ．３６３-３７１ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016034960A (ja) * 2009-08-10 2016-03-17 ビーエイチアイ リミテッド パートナーシップ １，３−プロパンジスルホン酸を送達するための方法、化合物、および組成物
JP2013521270A (ja) * 2010-03-05 2013-06-10 カンドュラ，マヘシュ 化合物、組成物、製剤、およびそれらの使用
JP2021024830A (ja) * 2019-08-07 2021-02-22 東ソー・ファインケム株式会社 カルボン酸無水物またはスルホン酸無水物の製造方法
JP7324082B2 (ja) 2019-08-07 2023-08-09 東ソー・ファインケム株式会社 カルボン酸無水物またはスルホン酸無水物の製造方法

Also Published As

Publication number Publication date
US9051248B2 (en) 2015-06-09
KR20120087878A (ko) 2012-08-07
ZA201201352B (en) 2014-04-30
JP2016034960A (ja) 2016-03-17
AU2010282170A1 (en) 2012-03-01
CN102471248B (zh) 2015-01-07
EA201290007A1 (ru) 2013-01-30
CN102471248A (zh) 2012-05-23
US20120208850A1 (en) 2012-08-16
EP2464626A4 (en) 2015-12-16
IL217572A (en) 2015-05-31
AU2010282170B2 (en) 2015-04-23
SG10201600910YA (en) 2016-03-30
NZ598085A (en) 2014-02-28
US20150266814A1 (en) 2015-09-24
MX2012001671A (es) 2012-04-30
CA2768877A1 (en) 2011-02-17
WO2011017800A1 (en) 2011-02-17
BR112012002780A2 (pt) 2017-02-21
EP2464626A1 (en) 2012-06-20
SG177645A1 (en) 2012-02-28

Similar Documents

Publication Publication Date Title
JP2016034960A (ja) １，３−プロパンジスルホン酸を送達するための方法、化合物、および組成物
JP6659792B2 (ja) ３−アミノ−１−プロパンスルホン酸を送達するための方法、化合物、組成物および媒体
AU2016279486B2 (en) Compounds for use in treating neuromuscular disorders
JP7688000B2 (ja) 非アポトーシス性の制御された細胞死の阻害剤としてのスピロキノキサリン誘導体
TR201808541T4 (tr) Nep (nötr endopeptidaz) inhibitörleri olarak ikame edilmiş bisfenil butanoik fosfonik asit türevleri.
US9233913B2 (en) Amino acid derivatives for the treatment of neuropathic pain
AU2015202454A1 (en) Methods, compounds, and compositions for delivering 1,3-propanedisulfonic acid
JP2025500888A (ja) 選択的ｐｈｄ１阻害剤としてのピコリンアミド化合物、組成物、及び使用方法
HK1133664B (en) Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
EP4043442A1 (en) 6-methyluracil derivatives with anticholinesterase activity and their use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130710

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130710

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141010

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141031

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150911

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150918

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20151030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161026

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20170425